Skip to main content

Table 4 Dose metrics for OARs; median and ranges and statistical outcomes for different energies and arc arrangements for prostate only (PO) plans

From: Class solutions for SABR-VMAT for high-risk prostate cancer with and without elective nodal irradiation

Structure

 

FA

PA300

PA210

Volume (cc)

 

10 F

6 F

6MV

10 F

6 F

6MV

10 F

6 F

6MV

Bladder

Mean (Gy)

4.1

4.3

4.3*

4.1

4.2

4.0

4.4҂

4.5*

4.6*

448.2

 

(2.6–8.7)

(2.7–8.8)

(2.7–8.8)

(2.4–8.7)

(2.6–8.7)

(2.6–8.6)

(2.5–9.0)

(2.6–9.2)

(2.6–9.2)

(234.3 − 566.0)

D2cc(Gy)

40.0

40.1

40.1

40.3

40.2

39.8

40.0

39.9

39.9

  

(39.6–40.6)

(39.4–40.5)

(39.5–40.6)

(39.4–40.6)

(39.6–40.6)

(39.5–40.2)

(39.3–40.2)

(39.4–40.3)

(39.5–40.4)

 

D95% (Gy)

0.2

0.4*

0.3*

0.2

0.3*

0.3

0.2

0.3*

0.3*

  

(0.1–0.6)

(0.2–0.8)

(0.2–0.8)

(0.1–0.6)

(0.2–0.8)

(0.2–0.8)

(0.1–0.6)

(0.2–0.9)

(0.2–0.8)

 

D50% (Gy)

0.8

1.1

1.1

0.8

1.1

0.9

0.8

1.1

1.1

  

(0.6–2.6)

(0.8–2.6)

(0.8–2.8)

(0.5–2.5)

(0.8–2.4)

(0.7–2.5)

(0.5–2.5)

(0.8–2.4)

(0.7–2.5)

 

V18.1Gy (%)

8.4

8.1

8.4

8.3

8.5

7.8

9.8 ɫ҂

9.7

10.0

  

(4.5–20.0)

(4.4–19.9)

(4.3–19.7)

(4.2–20.3)

(4.2–20.8)

(4.2–20.3)

(4.7–22.6)

(4.6–23.4)

(4.7–23.1)

 

V29Gy (%)

3.6

3.4

3.5*

3.7

3.6

3.0

4.0҂

4.0

4.0

  

(2.6–8.0)

(2.5–7.8)

(2.5–7.8)

(2.4–7.8)

(2.4–7.9)

(2.5–7.9)

(2.5–9.0)

(2.5–9.0)

(2.5–9.1)

 

V37Gy (cc)

7.4

7.5

7.5

7.5

7.4

6.6

7.1

7.1

7.2

  

(5.6–7.7)

(5.5–7.9)

(5.5–7.8)

(5.6–7.8)

(5.6–7.9)

(5.0–7.7)

(5.7–7.8)

(5.6–7.5)

(5.3–7.7)

Rectum

Mean(Gy)

16.0

16.0

15.8

14.4 ɫ

14.7

14.3

15.1 ɫ

14.8

14.7

57.9

 

(14.1–16.9)

(14.2–16.8)

(14.1–17.0)

(13.2–16.2)

(13.1–16.4)

(12.6–15.7)

(13.2–16.7)

(13.3–15.9)

(13.3–16.4)

(53.8–72.2)

D2cc (Gy)

35.6

35.7

35.7

35.6

35.6

35.0

35.8

35.9

35.8

  

(32.1–37.5)

(32.0–37.3)

(31.7–37.6)

(32.6–37.6)

(32.6–37.5)

(31.5–37.1)

(32.6–37.6)

(33.3–37.5)

(32.7–37.6)

 

D95% (Gy)

1.2

1.4

1.4*

1.1

1.4

1.4

1.2

1.4

1.4*

  

(1.0–1.9)

(1.2–2.0)

(1.3–2.2)

(1.0–1.9)

(1.2–2.0)

(1.3–1.7)

(1.0–2.1)

(1.2–2.0)

(1.2–2.1)

 

D50% (Gy)

15.7

15.7

15.3

14.2 ɫ

13.9

13.4

14.3 ɫ

13.4

13.7

  

(14.7–17.0)

(14.5–17.0)

(14.8–16.8)

(11.4–14.9)

(11.7–15.6)

(11.3–15.0)

(12.7–15.7)

(12.5–14.6)

(12.2–15.7)

 

V18.1Gy (%)

38.6

38.7

38.1

34.0

34.2

33.8

34.6 ɫ

30.6

31.1

  

(34.7–43.5)

(34.8–43.1)

(33.6–43.1)

(30.1–39.1)

(29.8–38.8)

(26.3–37.5)

(29.1–39.3)

(27.6–37.7)

(28.3–39.7)

 

V29Gy (%)

12.1

11.8

11.7

11.0

11.5

10.8

11.2

11.2

11.4

  

(6.6–15.4)

(6.3–15.3)

(6.1–15.1)

(7.2–16.2)

(7.1–15.0)

(6.2–14.2)

(6.6–15.6)

(7.4–15.9)

(6.9–15.8)

 

V36Gy (cc)

1.9

1.9

1.9

1.9

1.9

1.2

2.0

2.0

2.0

  

(0.6–2.7)

(0.7–2.7)

(0.6–2.7)

(0.6–2.7)

(0.8–2.7)

(0.6–2.4)

(0.9–2.8)

(0.9–2.8)

(0.8–2.8)

 

V38Gy (cc)

0.7

0.7

0.7

0.6

0.6

0.4

0.7

0.8

0.7

  

(0.1–1.3)

(0.1–1.2)

(0.1–1.3)

(0.1–1.3)

(0.1–1.3)

(0.1–1.0)

(0.2–1.3)

(0.2–1.3)

(0.2–1.4)

Sigmoid

Mean (Gy)

0.6

0.8*

0.8*

0.6

0.8*

0.8

0.6

0.8*

0.8*

106.1 (89.5–156.8)

 

(0.3–0.9)

(0.4–1.0)

(0.4–1.0)

(0.3–0.9)

(0.4–1.0)

(0.4–1.0)

(0.3–0.9)

(0.4–1.0)

(0.4–1.0)

Bowel

Mean (Gy)

0.1

0.2*

0.2*

0.2

0.2*

0.2

0.1

0.2*

0.2*

255.2 (95.1–376.9)

 

(0.1–0.2)

(0.2–0.3)

(0.1–0.2)

(0.2–0.2)

(0.1–0.2)

(0.1–0.2)

(0.1–0.2)

(0.2–0.2)

(0.1–0.2)

Rt Fem

Mean (Gy)

5.7

6.1

6.3

7.1

7.3

6.3

7.8 ɫ҂

8.0

8.0

52.6 (51.1–57.5)

 

(4.8–6.6)

(4.7–7.9)

(4.7–8.1)

(5.3–8.1)

(5.3–8.2)

(4.8–8.0)

(7.0–8.6)

(6.8–9.1)

(6.2–8.7)

Lt Fem

Mean (Gy)

6.4

6.5

6.1

6.6

7.1

6.5

7.4

7.8

7.4

55.1 (50.5–57.5)

 

(4.5–7.7)

(4.8–7.4)

(4.6–8.2)

(5.0–7.6)

(5.8–7.9)

(5.1–8.6)

(5.5–8.5)

(5.6–9.2)

(5.8–9.0)

Urethra

V42Gy (%)

0.1

0.1

0.0

3.1

0.0

0.0

5.6

1.3

3.0

0.4 (0.3–0.6)

 

(0.0–5.5)

(0.0–0.4)

(0.0–4.3)

(0.0–6.8)

(0.0–5.0)

(0.0–3.7)

(0.0–40.6)

(0.0–9.0)

(0–21.0)

NV Bundle

V38Gy (%)

32.2

33.7

31.5

27.3

33.6

27.0

24.9

40.2

40.0

0.8 (0.3–2.4)

 

(15.8–42.7)

(19.5–41.4)

(18.2–47.0)

(14.8–39.7)

(19.3–41.2)

(18.7–38.8)

(9.4–45.2)

(39.0–40.7)

(39.0–41.0)

  1. Abbreviations: FA full arc, PA300 300° partial arc, PA210 210° partial arc, D 2cc the dose received by the hottest 2 cc (near maximum dose), D X% the dose received by X% of the volume, V XGy the volume receiving dose XGy. Rt right, Lt left, Fem femoral head, NV Neurovascular, * = significantly different from 10 F plans (same arc arrangement), ɫ = significantly different from 10 F (FA) plans, ҂ = significantly different from 10 F (PA300) plans
  2. p ≤ 0.005 considered statistically significant (*, ɫ, ҂)